Cowen & Co. Reaffirms Their Buy Rating on Esperion (ESPR)


Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Esperion (ESPR) today and set a price target of $94. The company’s shares opened today at $45.81.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.3% and a 46.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, United Therapeutics, and G1 Therapeutics Inc.

Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $93.80, a 104.8% upside from current levels. In a report released today, Northland Securities also maintained a Buy rating on the stock with a $65 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $81.29 and a one-year low of $33.06. Currently, Esperion has an average volume of 567.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts